Biomarker qualification pilot process at the US Food and Drug Administration.
about
Generic approach to validation of small-molecule LC-MS/MS biomarker assays.Successes achieved and challenges ahead in translating biomarkers into clinical applications.Integrating ADNI results into Alzheimer's disease drug development programs.Mass-spectrometry-based clinical proteomics--a review and prospective.ISMRM workshop on fat-water separation: insights, applications and progress in MRI.Markers for nutrition studies: review of criteria for the evaluation of markers.Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trialsA pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials.A meta-analysis of CXCL12 expression for cancer prognosis.Biomarker method validation in anticancer drug developmentApplication of biomarkers in the development of drugs intended for the treatment of osteoarthritisMass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much?Biomarkers and updates on pediatrics lupus nephritis.Validation of analytic methods for biomarkers used in drug developmentIndustry perspectives on biomarker qualification.Searching for 'omic' biomarkersTissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.Biomarkers for drug-induced liver injury.Molecular biomarkers: a US FDA effort.Biomarkers: unrealized potential in sports doping analysis.Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics.Database searching for structural identification of metabolites in complex biofluids for mass spectrometry-based metabonomics.Metabolomics for early detection of drug-induced kidney injury: review of the current status.Bridging the translation gap - new hopes, new challenges.Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: what we know and what we need to know.Biomarkers and clinical tools in critically ill children: are we heading toward tailored drug therapy?An omics strategy for discovering pulmonary biomarkers potentially relevant to the evaluation of tobacco products.Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics.Biomarker-driven therapeutic management of Alzheimer's disease: establishing the foundations.Drug safety testing paradigm, current progress and future challenges: an overview.Building a roadmap to biomarker qualification: challenges and opportunities.Building bridges to the future of medicine: recommendations for boosting development of novel and companion diagnostics.Update on the clinical pharmacogenomics of organ transplantation.Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.Combining bioinformatics and MS-based proteomics: clinical implications.Mechanistic validation.Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis.Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF.Evaluation of novel urinary renal biomarkers with a cisplatin model of kidney injury: effects of collection period.Qualification of biomarkers for drug development in organ transplantation.
P2860
Q33748826-2AD66651-FFD8-4FA8-B40F-6B18D2FB2D0FQ33954585-59B63C8F-2133-4D43-9BB6-05B01A83B738Q33987409-B4EDB898-272D-4749-AEE3-4626DDC15BCAQ34252113-CA157BE9-6AFD-4DB8-8705-D9E4E0323B65Q34302041-18E8C68C-075D-4395-84E3-49F2FFC9F50BQ34364879-7DF6EB8C-BE40-4886-90E8-24F6E3B49006Q35532191-7C93B961-917C-4569-BC6E-ACA515CD7836Q35681400-52B419AA-F647-4556-A036-FF2EA9A3C790Q36378583-42AABFBA-7B3D-4F45-91B7-25CEE3E7F2C9Q36484621-3C36CA94-86D6-468F-BCD4-FE750247A234Q36598469-37F51FB2-6AE9-4A56-B910-3525B1F75FD8Q36807326-19142B24-1828-4799-BBBC-84AAF1FE885EQ37167062-A2E3CC9A-A46D-4C65-B028-30DDC8240685Q37284255-B899B525-73CF-4C89-A234-48BCBC50E6BAQ37341324-8E1DA6D4-994D-40E9-AFD6-E409F1B77CB5Q37517240-DB61248E-B57B-4D6F-A86C-346CBF72C143Q37554404-FB2FCA9E-23F8-4331-A4DB-CB0A3B0719C3Q37720754-7D4CF33C-6A2D-4D74-B60F-CB4A6C370CBDQ37734421-29A29907-2363-4F41-893B-EBA882DB55B7Q37810151-2C805274-41B8-4DB0-AF26-AFC088BDD1E2Q37810157-4332C170-BF61-425D-90BB-BD2DEE9FB132Q37810165-1345DA5E-8D39-4791-A607-6F623452B585Q37810166-4911E2E7-5983-4319-BA3B-2A50457A6378Q37820696-DBA4BFC3-7147-4C4D-99AA-230620BEE394Q37959015-6330BD31-D096-4FFA-9038-9732B0AE5CCAQ38021511-F48C9CCB-2147-4E0B-A304-2788E0BB0577Q38066244-3077EEB1-7A91-407D-B766-0A8D9B337ECAQ38122649-177E8F8E-D835-4E9B-BF8E-5BA6E235EE68Q38150708-C59BBBDE-3A44-4418-B753-12E45F53679CQ38207946-96A7A52C-3E34-44B8-B263-B2B17159111EQ38622968-2CE6CA20-3D54-4094-9244-EFD375C205A0Q39520804-89805B48-669F-4EA8-94F1-5B832804AE24Q39903042-2F8BB481-F32C-4193-AD8C-7A499FB13FD5Q42376623-F84A6A40-7863-4323-85AB-27E5DA9837C3Q42653805-D5FD31B2-D0AC-4F8D-9052-9A4FD6D2B575Q42725423-BA85D972-2CC1-4403-AEBF-64F40F71F074Q43663413-8C232B8D-50B0-484C-BB1D-AFA2220988E4Q43731070-883CE45D-A26D-486A-9E88-F4396359AC74Q44637841-167F6D5F-0193-4B58-8679-7DD3AB2DE06CQ45940767-18239911-F435-4B2D-A186-427318361867
P2860
Biomarker qualification pilot process at the US Food and Drug Administration.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Biomarker qualification pilot process at the US Food and Drug Administration.
@ast
Biomarker qualification pilot process at the US Food and Drug Administration.
@en
type
label
Biomarker qualification pilot process at the US Food and Drug Administration.
@ast
Biomarker qualification pilot process at the US Food and Drug Administration.
@en
prefLabel
Biomarker qualification pilot process at the US Food and Drug Administration.
@ast
Biomarker qualification pilot process at the US Food and Drug Administration.
@en
P356
P1433
P1476
Biomarker qualification pilot process at the US Food and Drug Administration.
@en
P2093
Federico Goodsaid
Felix Frueh
P2888
P304
P356
10.1208/AAPSJ0901010
P407
P577
2007-03-23T00:00:00Z
P5875
P6179
1018026052